Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Promising treatment strategies for hairy cell leukemia: BRAF inhibitors & combinations

Jan-Paul Bohn • 16 Jun 2023
ICML 2023
Hairy Cell Leukemia Leukemia Rare Diseases Antibodies

Jan-Paul Bohn, MD, PhD, The Medical University of Innsbruck, Innsbruck, Austria, comments on a promising treatment strategy for hairy cell leukemia (HCL), highlighting the role of BRAF inhibitors and options for combination therapies with these agents. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jan-Paul Bohn

2:11
Results from single-cell RNA sequencing analysis of hairy cell leukemia
Jan-Paul Bohn • 16 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals